For agencies that are "funded" by the companies they regulate, they sure give them a hard time and cost them a lot of money. Even the biggest pharmas spend a significant amount of resources erring on the side of caution over even minor details, so as to not have a regulator throw out their results and tell them to do it again. Which does happen sometimes.
Of course no research review is flawless. If your standard is flawless, you're deliberately setting an impossible standard for no discernable concrete benefit. But it's rigorous, public, and the regulators have the authority to pull treatments off the market if post-approval research has troubling results. Which they do sometimes.
This sort of asinine concern trolling is a serious danger to public health. It would be one thing if it was valid criticisms, of which there are plenty, combined with realistic proposals for alternatives. But it never is, and now we have nearly or previously eradicated diseases making a comeback.
They are almost certainly not actually working that much though. Look up the recent Massachusetts state police overtime scandal.